COMMENTARY

Is Case of Leqembi a “Steppingstone” to New CEA Price Adjustment Rule? Pharma Industry on Guard

By Yoshinori Sagehashi January 30, 2024

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The pharmaceutical industry seems to appreciate the Japanese government’s FY2024 reform plans for the drug pricing system, but apparently not those for the cost-effectiveness assessment (CEA) scheme. It is because pharma officials can see the government’s obvious intention to review…

To read the full story

Leqembi Likely to Face 15% Price Cut Under Special CEA Rule
July 10, 2025
Leqembi to Cost 2.98 Million Yen per Year, Re-Pricing Might Be Triggered on Patient Upswing
December 14, 2023
FY2024 CEA Reform Outline OK’ed, Price Adjustment Range Up for Continued Debate
December 14, 2023

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026
January 6, 2026
Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise
December 22, 2025
FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed
December 9, 2025
MOF Autumn Proposals Signal a Shift from Drug Pricing to Cost-Sharing Reform
November 17, 2025
Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
November 10, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…